Impact of <scp>SARS‐CoV</scp>‐2 infection in children with psoriasis: Results of a monocentric experience

Caroppo, Francesca; Fagotto, Laura; Tartaglia, Jacopo; Mazzetto, Roberto; Fortina, Anna Belloni

doi:10.1111/jdv.18874

Cited by 2 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the impact of COVID-19 infection on psoriasis remains uncertain, so it is critical for patients with chronic psoriasis to use a treatment to maintain stability during COVID-19 infection. There is actually very little data on the use of biologics to treat psoriasis patients during COVID-19 infection (11).…”

Section: Discussionmentioning

confidence: 99%

Biologics targeting IL-17 and IL-23 maintain stability in patients with psoriasis during COVID-19 infection: a case-control study

Huang,

Yu,

et al. 2023

Front. Med.

View full text Add to dashboard Cite

BackgroundPsoriasis is a chronic and refractory skin disease. The emergence of biologics provides more options for the treatment of psoriasis, but the COVID-19 pandemic poses challenges for the management of psoriasis.ObjectivesThe purpose of this study was to investigate the effect of different biologics on the stabilization of psoriasis during COVID-19 infection in China.MethodsThis is a single-center, observational, retrospective, case–control study. Using our database, we conducted a remote dermatologic study by means of questionnaire follow-up or telephone follow-up to collect general information of patients, information related to COVID-19 infection and conditions of psoriasis for comparison and further analysis between groups.ResultsOur study ultimately included 274 patients for analysis. We found that the patients in this collection had mild symptoms of COVID-19 infection, and only 13 of them needed to go to the hospital for medical treatment. Further studies found that in biologics, relative to tumor necrosis factor-α inhibitors (TNF-αi), interleukin-17 inhibitors (IL-17i) and interleukin-23 inhibitors (IL-23i) are both protective factors in flare-up of psoriasis [IL-17i: OR (95% CI) = 0.412 (0.189–0.901); IL-23i: OR (95% CI) = 0.291 (0.097–0.876)]. In addition, we also found that the proportion of people with increased psoriasis developing long COVID-19 increased, and we speculated that increased psoriasis may be a potential risk factor for long COVID-19.ConclusionOur study showed that the use of IL-17i and IL-23i was a protective factor for psoriasis compared with TNF-αi, and could keep the psoriasis stable.

show abstract

Section: Discussionmentioning

confidence: 99%

Biologics targeting IL-17 and IL-23 maintain stability in patients with psoriasis during COVID-19 infection: a case-control study

Huang,

Yu,

et al. 2023

Front. Med.

View full text Add to dashboard Cite

show abstract

“…In the version of this article initially published, 1 Dr. Francesca Caroppo affiliation was listed as ‘Pediatric Dermatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy’. Her correct affiliation is the 1 Pediatric Dermatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy and Department of Women's and Children's Health SDB‐University of Padova.…”

mentioning

confidence: 99%

Corrigendum: Impact of SARS‐CoV‐2 infection in children with psoriasis: Results of a monocentric experience

2023

Acad Dermatol Venereol

View full text Add to dashboard Cite

Impact of SARS‐CoV‐2 infection in children with psoriasis: Results of a monocentric experience

Cited by 2 publications

References 4 publications

Biologics targeting IL-17 and IL-23 maintain stability in patients with psoriasis during COVID-19 infection: a case-control study

Biologics targeting IL-17 and IL-23 maintain stability in patients with psoriasis during COVID-19 infection: a case-control study

Corrigendum: Impact of SARS‐CoV‐2 infection in children with psoriasis: Results of a monocentric experience

Contact Info

Product

Resources

About